Familial hypercholesterolemia and elevated lipoprotein(a): double heritable risk and new therapeutic opportunities

Lipoprotein(a), PCSK9 Inhibition and Cardiovascular Risk: Insights from the FOURIER Trial

(2019) Michelle L. O'Donoghue et al.   CIRCULATION

Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among Seven Ethnic Groups

(2019) Guillaume Paré et al.   CIRCULATION

Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease

(2019) Michael B. Boffa et al.   Nature Reviews Cardiology

Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a)

(2019) Elisa Waldmann et al.   PATHOLOGY

New Frontiers in Lp(a)-Targeted Therapies

(2019) Matthew J. Borrelli et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

HIGHER LIPOPROTEIN (A) LEVEL IS ASSOCIATED WITH HIGHER PREVALENCE OF VULNERABLE PLAQUE PARTICULARLY IN PATIENTS WITH HIGHER LDL CHOLESTEROL LEVEL

(2019) Yusuke Muramatsu et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Value of Measuring Lipoprotein(a) During Cascade Testing for Familial Hypercholesterolemia

(2019) Katrina L. Ellis et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Lp(a) and cardiovascular disease—Has the phoenix finally risen from the ashes?

(2019) Osman Najam et al.   EUROPEAN HEART JOURNAL

Race-Based Differences in Lipoprotein(a)-Associated Risk of Carotid Atherosclerosis

(2019) Brian T. Steffen et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Statin therapy increases lipoprotein(a) levels

(2019) Sotirios Tsimikas et al.   EUROPEAN HEART JOURNAL

Is Lp(a) ready for prime time use in the clinic? A pros-and-cons debate

(2018) Karam M. Kostner et al.   ATHEROSCLEROSIS

RNA-Targeted Therapeutics

(2018) Stanley T. Crooke et al.   Cell Metabolism

Controlled study of the effect of proprotein convertase subtilisin-kexin type 9 inhibition with evolocumab on lipoprotein(a) particle kinetics

(2018) Gerald F Watts et al.   EUROPEAN HEART JOURNAL

Impact of age on excess risk of coronary heart disease in patients with familial hypercholesterolaemia

(2018) Liv J Mundal et al.   HEART

Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017

(2018) Mariko Harada-Shiba et al.   Journal of Atherosclerosis and Thrombosis

Relationship between “LDL-C”, estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide

(2018) Nicholas J. Viney et al.   Journal of Clinical Lipidology

NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis

(2018) Sotirios Tsimikas et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Present therapeutic role of cholesteryl ester transfer protein inhibitors

(2018) Nicola Ferri et al.   PHARMACOLOGICAL RESEARCH

Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies

(2018) Stephen Burgess et al.   JAMA Cardiology

Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal

(2018) Michael B. Boffa et al.   Journal of Clinical Lipidology

Guidance on the management of familial hypercholesterolaemia in Hong Kong: an expert panel consensus viewpoint

(2018) Brian Tomlinson et al.   HONG KONG MEDICAL JOURNAL

Canadian Cardiovascular Society Position Statement on Familial Hypercholesterolemia: Update 2018

(2018) Liam R. Brunham et al.   CANADIAN JOURNAL OF CARDIOLOGY

High lipoprotein(a) and high risk of mortality

(2018) Anne Langsted et al.   EUROPEAN HEART JOURNAL

Persistent arterial wall inflammation in patients with elevated lipoprotein(a) despite strong low-density lipoprotein cholesterol reduction by proprotein convertase subtilisin/kexin type 9 antibody treatment

(2018) Lotte C A Stiekema et al.   EUROPEAN HEART JOURNAL

ClinVar database of global familial hypercholesterolemia-associated DNA variants

(2018) Michael A. Iacocca et al.   HUMAN MUTATION

JCL roundtable—Lipoprotein(a): The emerging risk factor

(2018) Santica M. Marcovina et al.   Journal of Clinical Lipidology

Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials

(2018) Peter Willeit et al.   LANCET

Lipoprotein(a): lodestar for future clinical trials

(2018) Gerald F Watts et al.   LANCET

Lipoprotein(a) catabolism: a case of multiple receptors

(2018) Sally P.A. McCormick et al.   PATHOLOGY

Lipoprotein(a) as a risk factor for calcific aortic valvulopathy in heterozygous familial hypercholesterolemia

(2018) Alpo Vuorio et al.   ATHEROSCLEROSIS

Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a)

(2017) Alpo Vuorio et al.   EUROPEAN HEART JOURNAL

2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia

(2017) Ulf Landmesser et al.   EUROPEAN HEART JOURNAL

Systematic Screening for Familial Hypercholesterolaemia and Elevated Lp(a) in Families

(2017) K. Ellis et al.   Heart Lung and Circulation

A Test in Context: Lipoprotein(a)

(2017) Sotirios Tsimikas   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

(2017) Kausik K. Ray et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

(2017)   NEW ENGLAND JOURNAL OF MEDICINE

Lipoprotein(a) and inflammation: A dangerous duet leading to endothelial loss of integrity

(2017) Matteo Pirro et al.   PHARMACOLOGICAL RESEARCH

Roles of the low density lipoprotein receptor and related receptors in inhibition of lipoprotein(a) internalization by proprotein convertase subtilisin/kexin type 9

(2017) Rocco Romagnuolo et al.   PLoS One

Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis

(2017) Leo E Akioyamen et al.   BMJ Open

Genetic Architecture of Familial Hypercholesterolaemia

(2017) Mahtab Sharifi et al.   Current Cardiology Reports

Efficacy and Safety of Alirocumab in Japanese Subjects (Phase 1 and 2 Studies)

(2016) Tamio Teramoto et al.   AMERICAN JOURNAL OF CARDIOLOGY

2016 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in the Adult

(2016) Todd J. Anderson et al.   CANADIAN JOURNAL OF CARDIOLOGY

Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia and LDL-C of 160 mg/dl or Higher

(2016) Henry N. Ginsberg et al.   CARDIOVASCULAR DRUGS AND THERAPY

LPA Gene, Ethnicity, and Cardiovascular EventsClinical Perspective

(2016) Sang-Rok Lee et al.   CIRCULATION

Effects of PCSK9 Inhibition With Alirocumab on Lipoprotein Metabolism in Healthy HumansClinical Perspective

(2016) Gissette Reyes-Soffer et al.   CIRCULATION

Lipoprotein(a) in Familial Hypercholesterolemia With Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Gain-of-Function Mutations

(2016) Hayato Tada et al.   CIRCULATION JOURNAL

The central role of arterial retention of cholesterol-rich apolipoprotein-B-containing lipoproteins in the pathogenesis of atherosclerosis

(2016) Jan Borén et al.   CURRENT OPINION IN LIPIDOLOGY

Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217

(2016) Marianne Benn et al.   EUROPEAN HEART JOURNAL

International Developments in the Care of Familial Hypercholesterolemia: Where Now and Where to Next?

(2016) Jing Pang et al.   Journal of Atherosclerosis and Thrombosis

Familial combined hyperlipidemia and hyperlipoprotein(a) as phenotypic mimics of familial hypercholesterolemia: Frequencies, associations and predictions

(2016) Katrina L. Ellis et al.   Journal of Clinical Lipidology

Familial hypercholesterolemia among unselected contemporary patients presenting with first myocardial infarction: Prevalence, risk factor burden, and impact on age at presentation

(2016) Martin Bødtker Mortensen et al.   Journal of Clinical Lipidology

The very high cardiovascular risk in heterozygous familial hypercholesterolemia: Analysis of 734 French patients

(2016) Sophie Béliard et al.   Journal of Clinical Lipidology

Structure, function, and genetics of lipoprotein (a)

(2016) Konrad Schmidt et al.   JOURNAL OF LIPID RESEARCH

Lipoprotein (a) as a cause of cardiovascular disease: insights from epidemiology, genetics, and biology

(2016) Børge G. Nordestgaard et al.   JOURNAL OF LIPID RESEARCH

Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia

(2016) Amit V. Khera et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

(2016) Nicholas J Viney et al.   LANCET

Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials

(2016) Amirhosssein Sahebkar et al.   METABOLISM-CLINICAL AND EXPERIMENTAL

Progress in the care of common inherited atherogenic disorders of apolipoprotein B metabolism

(2016) Katrina L. Ellis et al.   Nature Reviews Endocrinology

Child–Parent Familial Hypercholesterolemia Screening in Primary Care

(2016) David S. Wald et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lp(a) and cardiovascular risk: Investigating the hidden side of the moon

(2016) M. Bucci et al.   NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES

The re-emergence of lipoprotein(a) in a broader clinical arena

(2016) Sotirios Tsimikas   PROGRESS IN CARDIOVASCULAR DISEASES

Lipoprotein(a) Interactions With Low‐Density Lipoprotein Cholesterol and Other Cardiovascular Risk Factors in Premature Acute Coronary Syndrome (ACS)

(2016) Mehdi Afshar et al.   Journal of the American Heart Association

Race Is a Key Variable in Assigning Lipoprotein(a) Cutoff Values for Coronary Heart Disease Risk AssessmentSignificance

(2015) Weihua Guan et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Lipoprotein (a) levels are not associated with carotid plaques and carotid intima media thickness in statin-treated patients with familial hypercholesterolemia

(2015) Sven Bos et al.   ATHEROSCLEROSIS

Specific Lipoprotein(a) apheresis attenuates progression of carotid intima-media thickness in coronary heart disease patients with high lipoprotein(a) levels

(2015) M.V. Ezhov et al.   ATHEROSCLEROSIS SUPPLEMENTS

The Agenda for Familial Hypercholesterolemia

(2015) Samuel S. Gidding et al.   CIRCULATION

‘LDL-C’ = LDL-C + Lp(a)-C

(2015) Calvin Yeang et al.   CURRENT OPINION IN LIPIDOLOGY

Screening and advanced lipid phenotyping in familial hypercholesterolemia: The Very Large Database of Lipids Study-17 (VLDL-17)

(2015) P. Elliott Miller et al.   Journal of Clinical Lipidology

Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia

(2015) R. Vongpromek et al.   JOURNAL OF INTERNAL MEDICINE

Lipoprotein (a) measurements for clinical application

(2015) Santica M. Marcovina et al.   JOURNAL OF LIPID RESEARCH

Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans

(2015) Mark J. Graham et al.   JOURNAL OF LIPID RESEARCH

Lipoprotein (a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis

(2015) George Thanassoulis   JOURNAL OF LIPID RESEARCH

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study

(2015) Sotirios Tsimikas et al.   LANCET

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

(2015) Frederick J Raal et al.   LANCET

Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events

(2015) Jennifer G. Robinson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events

(2015) Marc S. Sabatine et al.   NEW ENGLAND JOURNAL OF MEDICINE

Structural analysis of APOB variants, p.(Arg3527Gln), p.(Arg1164Thr) and p.(Gln4494del), causing Familial Hypercholesterolaemia provides novel insights into variant pathogenicity

(2015) J. A. Fernández-Higuero et al.   Scientific Reports

Integrated guidance on the care of familial hypercholesterolemia from the International FH Foundation

(2014) Gerald F. Watts et al.   Journal of Clinical Lipidology

Lipoprotein(a) Levels in Familial Hypercholesterolemia

(2014) Rodrigo Alonso et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography

(2013) Maya S. Safarova et al.   ATHEROSCLEROSIS SUPPLEMENTS

Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease

(2013) Josef Leebmann et al.   CIRCULATION

Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension

(2013) Raul D. Santos et al.   EUROPEAN HEART JOURNAL

Diagnosis and treatment of familial hypercholesterolaemia

(2013) G. Kees Hovingh et al.   EUROPEAN HEART JOURNAL

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society

(2013) B. G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

Extreme Lipoprotein(a) Levels and Improved Cardiovascular Risk Prediction

(2013) Pia R. Kamstrup et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Polygenic familial hypercholesterolaemia: does it matter?

(2013) Evan A Stein et al.   LANCET

Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study

(2013) Philippa J Talmud et al.   LANCET

Statin treatment of children with familial hypercholesterolemia – Trying to balance incomplete evidence of long-term safety and clinical accountability: Are we approaching a consensus?

(2012) Alpo Vuorio et al.   ATHEROSCLEROSIS

INTERIM Guidelines for the Diagnosis and Management of Familial Hypercholesterolaemia

(2012) David R. Sullivan et al.   Heart Lung and Circulation

Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia

(2012) Kiyohito Arai et al.   JOURNAL OF LIPID RESEARCH

Lipoprotein(a) as a Potential Causal Genetic Risk Factor of Cardiovascular Disease

(2012) Sotirios Tsimikas et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Oxidized Phospholipids Are Present on Plasminogen, Affect Fibrinolysis, and Increase Following Acute Myocardial Infarction

(2012) Gregor Leibundgut et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Large-scale association analysis identifies new risk loci for coronary artery disease

(2012) Panos Deloukas et al.   NATURE GENETICS

Management of familial hypercholesterolemia in children and young adults: Consensus paper developed by a panel of lipidologists, cardiologists, paediatricians, nutritionists, gastroenterologists, general practitioners and a patient organization

(2011) O.S. Descamps et al.   ATHEROSCLEROSIS

The role of lipoprotein(a) in the formation of arterial plaques, stenoses and occlusions

(2011) J. David Spence   CANADIAN JOURNAL OF CARDIOLOGY

Associations Between Lipoprotein(a) Levels and Cardiovascular Outcomes in Black and White Subjects

(2011) Salim S. Virani et al.   CIRCULATION

Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients

(2011) Anne C. Goldberg et al.   Journal of Clinical Lipidology

Lipoprotein(a) as a cardiovascular risk factor: current status

(2010) Børge G. Nordestgaard et al.   EUROPEAN HEART JOURNAL

Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality

(2009)   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events

(2009) Beate R Jaeger et al.   Nature Reviews Cardiology

Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease

(2009) Robert Clarke et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lipoprotein(a) Is Associated Differentially With Carotid Stenosis, Occlusion, and Total Plaque Area

(2008) Jonathan H. Klein et al.   ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY

Lipid Screening and Cardiovascular Health in Childhood

(2008) S. R. Daniels et al.   PEDIATRICS